Gun H Na1, Eun Y Kim1, Tae H Hong1, Young K You1, Dong G Kim2. 1. Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. 2. Department of Surgery, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea. Electronic address: kimdg@catholic.ac.kr.
Abstract
BACKGROUND: We evaluated the effects of pre-transplant locoregional treatment on survival in living donor liver transplantation (LDLT), and the most accurate method for predicting survival after LDLT in patients who received pre-transplant locoregional treatment. METHODS: From December 2003 to December 2012, 234 patients underwent LDLT for hepatocellular carcinoma (HCC) at our transplant center. We retrospectively reviewed 86 patients newly diagnosed with HCC and who received pre-transplant locoregional treatments at our hospital. RESULTS: Of the 33 patients with HCC initially beyond the Milan criteria, 12 experienced successful down-staging after locoregional treatments, and the 5-year recurrence-free survival was 81.8%, which was comparable to those in patients with HCC initially within the Milan criteria. A bad responder according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [HR, 4.874 (1.059-22.442), p = 0.042], and increased AFP levels [HR 4.002 (1.540-10.397), p = 0.004] during pre-transplant locoregional treatments were independent risk factors for HCC recurrence after LDLT in multivariate analysis. CONCLUSIONS: Liver transplantation may be considered after successful down-staging in patients with HCC initially beyond the Milan criteria. The mRECIST and serum AFP level changes are better selection criteria for LDLT in patients who have received locoregional treatments.
BACKGROUND: We evaluated the effects of pre-transplant locoregional treatment on survival in living donor liver transplantation (LDLT), and the most accurate method for predicting survival after LDLT in patients who received pre-transplant locoregional treatment. METHODS: From December 2003 to December 2012, 234 patients underwent LDLT for hepatocellular carcinoma (HCC) at our transplant center. We retrospectively reviewed 86 patients newly diagnosed with HCC and who received pre-transplant locoregional treatments at our hospital. RESULTS: Of the 33 patients with HCC initially beyond the Milan criteria, 12 experienced successful down-staging after locoregional treatments, and the 5-year recurrence-free survival was 81.8%, which was comparable to those in patients with HCC initially within the Milan criteria. A bad responder according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [HR, 4.874 (1.059-22.442), p = 0.042], and increased AFP levels [HR 4.002 (1.540-10.397), p = 0.004] during pre-transplant locoregional treatments were independent risk factors for HCC recurrence after LDLT in multivariate analysis. CONCLUSIONS: Liver transplantation may be considered after successful down-staging in patients with HCC initially beyond the Milan criteria. The mRECIST and serum AFP level changes are better selection criteria for LDLT in patients who have received locoregional treatments.
Authors: Gunda Millonig; Ivo W Graziadei; Martin C Freund; Werner Jaschke; Sylvia Stadlmann; Ruth Ladurner; Raimund Margreiter; Wolfgang Vogel Journal: Liver Transpl Date: 2007-02 Impact factor: 5.799
Authors: M Ravaioli; G L Grazi; F Piscaglia; F Trevisani; M Cescon; G Ercolani; M Vivarelli; R Golfieri; A D'Errico Grigioni; I Panzini; C Morelli; M Bernardi; L Bolondi; A D Pinna Journal: Am J Transplant Date: 2008-12 Impact factor: 8.086
Authors: Gerd Otto; Sascha Herber; Michael Heise; Ansgar W Lohse; Christian Mönch; Fernando Bittinger; Maria Hoppe-Lotichius; Marcus Schuchmann; Anja Victor; Michael Pitton Journal: Liver Transpl Date: 2006-08 Impact factor: 5.799
Authors: F Y Yao; L Ferrell; N M Bass; J J Watson; P Bacchetti; A Venook; N L Ascher; J P Roberts Journal: Hepatology Date: 2001-06 Impact factor: 17.425
Authors: Francis Y Yao; Robert K Kerlan; Ryutaro Hirose; Timothy J Davern; Nathan M Bass; Sandy Feng; Marion Peters; Norah Terrault; Chris E Freise; Nancy L Ascher; John P Roberts Journal: Hepatology Date: 2008-09 Impact factor: 17.425
Authors: Fabio Farinati; Dario Marino; Massimo De Giorgio; Anna Baldan; Maria Cantarini; Carmela Cursaro; Gianludovico Rapaccini; Paolo Del Poggio; Maria Anna Di Nolfo; Luisa Benvegnù; Marco Zoli; Franco Borzio; Mauro Bernardi; Franco Trevisani Journal: Am J Gastroenterol Date: 2006-03 Impact factor: 10.864
Authors: E Vibert; D Azoulay; E Hoti; S Iacopinelli; D Samuel; C Salloum; A Lemoine; H Bismuth; D Castaing; R Adam Journal: Am J Transplant Date: 2010-01 Impact factor: 8.086
Authors: V Mazzaferro; E Regalia; R Doci; S Andreola; A Pulvirenti; F Bozzetti; F Montalto; M Ammatuna; A Morabito; L Gennari Journal: N Engl J Med Date: 1996-03-14 Impact factor: 176.079
Authors: Mohammad Kamal Shaker; Iman F Montasser; Mohamed Sakr; Mohamed Elgharib; Hany M Dabbous; Hend Ebada; Ahmed El Dorry; Mohamed Bahaa; Mahmoud El Meteini Journal: J Hepatocell Carcinoma Date: 2018-02-27
Authors: Astrid Bauschke; Annelore Altendorf-Hofmann; Michael Ardelt; Herman Kissler; Hans-Michael Tautenhahn; Utz Settmacher Journal: J Cancer Res Clin Oncol Date: 2020-04-30 Impact factor: 4.553
Authors: Min Suk Chae; Kwang Uck Moon; Hyun Sik Chung; Chul Soo Park; Jaemin Lee; Jong Ho Choi; Sang Hyun Hong Journal: PLoS One Date: 2018-04-12 Impact factor: 3.240